Barclays Raises Danaher (NYSE:DHR) Price Target to $270.00

Danaher (NYSE:DHR) had its price objective raised by research analysts at Barclays from $260.00 to $270.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has an “equal weight” rating on the conglomerate’s stock. Barclays‘s price objective suggests a potential upside of 8.38% from the stock’s previous close.

Several other brokerages also recently weighed in on DHR. Robert W. Baird increased their price target on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Royal Bank of Canada lifted their price target on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Citigroup lifted their price target on Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Finally, KeyCorp upped their price objective on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Six analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $268.67.

Danaher Stock Down 1.6 %

Shares of NYSE:DHR traded down $3.98 on Wednesday, hitting $249.13. 1,122,664 shares of the company traded hands, compared to its average volume of 2,755,977. Danaher has a 52 week low of $182.09 and a 52 week high of $259.00. The stock has a 50 day simple moving average of $248.95 and a 200-day simple moving average of $230.64. The company has a market cap of $184.49 billion, a PE ratio of 39.08, a PEG ratio of 3.96 and a beta of 0.83. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter in the previous year, the company posted $2.36 EPS. The company’s revenue was down 2.6% compared to the same quarter last year. As a group, research analysts expect that Danaher will post 7.62 earnings per share for the current year.

Insider Activity

In other Danaher news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares in the company, valued at $9,601,704. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Danaher news, Director Teri List sold 3,289 shares of the stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the sale, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The disclosure for this sale can be found here. In the last three months, insiders sold 32,957 shares of company stock worth $8,265,802. 10.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. ST Germain D J Co. Inc. grew its position in shares of Danaher by 1.4% during the first quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock worth $719,000 after acquiring an additional 41 shares during the last quarter. Godsey & Gibb Inc. lifted its stake in Danaher by 3.0% during the first quarter. Godsey & Gibb Inc. now owns 1,442 shares of the conglomerate’s stock valued at $360,000 after buying an additional 42 shares in the last quarter. Nicholas Hoffman & Company LLC. lifted its stake in Danaher by 2.3% during the fourth quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock valued at $439,000 after buying an additional 43 shares in the last quarter. Los Angeles Capital Management LLC lifted its position in shares of Danaher by 1.3% in the fourth quarter. Los Angeles Capital Management LLC now owns 3,470 shares of the conglomerate’s stock worth $803,000 after purchasing an additional 43 shares in the last quarter. Finally, Berger Financial Group Inc lifted its position in shares of Danaher by 1.7% in the fourth quarter. Berger Financial Group Inc now owns 2,517 shares of the conglomerate’s stock worth $582,000 after purchasing an additional 43 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.